Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Kalaivani Mahadevan and Sofia Papadopoulou provide their take on the INVEST CTO trial, presented by Anja Oksnes at TCT 2025, in San Francisco.

Results of the interim analyses performed after 12 months in the first 111 patients enrolled in phase II Cool AMI trial evaluating safety and effectiveness of systemic therapeutic hypothermia as an adjunctive therapy in anterior STEMI undergoing PCI as compared to PCI only. Analyses showed significant...

View the case of this 65-year-old male patient who was staged for R-PCI of a Medina 1,1,1 distal left main lesion, and discover how the authors used a hybrid robotic and manual approach to perform a DK crush procedure using the second-generation R-PCI device.

Luigi Biasco provides his take on the results of the EARLY TAVR trial, presented by Philippe Genereux at TCT 2024 in Washington.

How do you navigate the complexities of performing TAVI on aortas previously treated for coarctation surgery, while ensuring patient safety through meticulous planning and expert precision? Analyse this image to find out more!

Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

Reported from ACC 2023 / WCC

Edoardo Zancanaro provides his take on this clinical trial presented by Enoch Akowuah at the American College of Cardiology Scientific Session (ACC.23/WCC).

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.

The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...

Complex percutaneous coronary intervention (PCI) procedures are dramatically increasing in daily practice. Calcified coronary artery lesions and hostile cardiac anatomy may increase the risk of device dislodgment and/or malposition. In such situations, the use of a snare catheter is pivotal to retrieve and/or reposition the device.

Aaysha Cader and Ali Nazmi Calik provide their take on the BHF PROTECT-TAVI trial, presented by Rajesh Kharbanda at ACC.25 in Chicago.

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Mirvat Alasnag provides her take on the ECMO-CS trial, which was presented during AHA 2022 in Chicago, and simultaneously published in Circulation. 

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Ali Nazmi Calik provides his take on OPTION, which was presented during AHA 2022 in Chicago.